Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center , University Medical Center, shared on X:
“Atezolizumab versus durvalumab plus platinum etoposide in extensive stage SCLC by Hirano and colleagues on JJCO.
Take: Japan real-world, propensity-matched n=128, mOS 13.9 vs 14.8 mo, p=0.92;
- monthly cost $7,183 vs $11,422;
- grade 2 or higher irAE 11% vs 31%;
- ILD 3% vs 20%.

Same survival, but atezolizumab was cheaper and notably less pneumonitis. I think this will be an interesting idea to develop between IMforte and Dellphi 305 does the immunotherapy backbone matter? Also might be useful in countries that cost is a limitation.”
Title: Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes
Authors: Katsuya Hirano, Akito Hata, Yuta Yamanaka, Toshiyuki Sumi, Motohiro Tamiya, Yuki Sato, Yuko Oya, Kosuke Hamai, Nobuyuki Katakami, Katsuhiko Iwasaki, Tatsuhiro Uenishi, Kinya Kokubo, Ataru Igarashi
- DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
- NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
